BLRX
BioLineRx Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$2.02
+0.50%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$2.01
From 52W high−46.56%
Volume34641.00
Market cap$10.06M
P/E (TTM)—
P/S (TTM)8.5x
Div yield—
Key dataOct 19, 2026
Open
$2.01
From 52W high
−46.56%
Volume
34641.00
Market cap
$10.06M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−34.6x
P/E (TTM)
—
RSI (14)
23.2
MomentumView details →
1D Return
+0.50%
YTD Return
−29.24%
SummaryUpdated Jun 1, 2026
BioLineRx Ltd. (NASDAQ:BLRX) is a clinical-stage biopharmaceutical company founded in 2003 and headquartered in Hevel Modi'in, Israel. The company has undergone a significant strategic transformation from a development-focused biotech to a hybrid commercial and development organization. Following FDA approval of its lead drug APHEXDA in September 2023, BioLineRx successfully launched its first commercial product while simultaneously executing a major licensing deal with Ayrmid Pharma in 2024 that fundamentally reshaped its business model and financial profile.
Similar companies
Latest newsMore news →
BioLineRx reported its unaudited financial results for the quarter ended June 30, 2026, and provided a corporate update.49d agoBioLineRx Ltd. announced a registered direct offering and concurrent private placement of 1,348,921 American Depositary Shares at $2.78 per ADS, raising approximately $3.75 million.52d ago